Adebrelimab
S-1
Meng QiuPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the S-1 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
S-1 Meng Qiu | Phase 2 | CCC |
Fruquintinib Meng Qiu | Phase 2 | CCC |
TRASTUZUMAB Aiping Zhou | Phase 2 | CCC |
Eloxatin Aiping Zhou | Phase 2 | CCC |
Catequentinib The First People's Hospital of Lianyungang | Phase 2 | CCC |
Raltitrexed Meng Qiu | Phase 2 | CCC |
Same molecule, other indications
Adebrelimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →